/
GALT
$3.53+$0.39 (+12.42%)prev close
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$316.7M
101M shares
52-week range
$2.03 – $7.13
29% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Change+$0.24
Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
www.galectintherapeutics.com- Employees
- 9
- IPO / List date
- Sep 4, 2002
- HQ
- NORCROSS, GA
Held by traders on TradeandTell
No one on the platform currently holds GALT.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 147,900 | $412.6K |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2012-03-23 | 1-for-6reverse |
Recent trades on TradeandTell
No one on the platform has traded GALT yet.
